[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606341":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":30,"locations":11,"responsibleParty":36,"collaborators":38,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":11},{"fullName":5,"class":6},"Getz Pharma","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"assignment of participants to treatment group A (Acotiamide)","ACTIVE_COMPARATOR",null,[13],"Drug: Acotiamide",{"label":15,"type":10,"description":11,"interventionNames":16},"assignment of participants to treatment group B (Itopride).",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Acotiamide","Both these drugs are used for the management of PDS type of FD",[9,15],[24],"Itopride",[26],{"name":27,"affiliation":28,"role":29},"Prof. Dr. Muahmmad Umar, MBBS, FCPS, FACG, AGAF, FRCP","Rawalpindi Medical University\u002FCollege","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":11,"email":35},"Mahaveer MR Maheshwari, MBBS","CONTACT","+923202521918","mahaveer.maheshwari@getzpharma.com",{"type":37,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[39],{"name":40,"class":41},"Rawalpindi Medical College, Pakistan","OTHER","100606341","phase-3-acotiamide-vs-itopride-in-postprandial-distress-syndrome-100606341",false,"NCT07174297","Acotiamide vs Itopride in Postprandial Distress Syndrome","To Compare the Efficacy and Safety of Acotiamide Versus Itopride in Patient With Post Prandial Distress Syndrome Type of Functional Dyspepsia","Inclusion Criteria:\n\n* Subjects to provide written informed consent prior to any study procedures being performed\n* Subjects with age 18-70 both male and female\n* Diagnosed with FD (PDS) by using ROME IV criteria\n* Subjects naive to acotiamide and Itopride for last 2 weeks\n* Subjects must have a normal endoscopy result within the 6 months\n\nExclusion Criteria:\n\n* Without predominant symptoms of ulcer and GERD based on history \\& endoscopy, IBS based on history \\& Rome IV criteria and Chronic idiopathic nausea based on history only\n* Subjects taking drugs that affect gut motility, gut sensitivity, SSRI and\u002For acid secretion who are unable to discontinue these drugs before initiating the intervention\n* Subjects with chronic medical disorders potentially contributing to PDS such as chronic pancreatitis, hypothyroidism, CKD and CLD identified through clinical history, physical examination, or previous medical records\n* Subjects with Type I or Type II diabetes\n* Pregnant \\& lactating mothers","ALL","18 Years","70 Years",{"count":53,"type":54},152,"ESTIMATED","INTERVENTIONAL",[57],"PHASE3","The goal of this study is to \"To compare the efficacy and safety of Acotiamide versus Itopride in patient with post prandial distress syndrome type of functional dyspepsia\"",[60],"Postprandial Distress Syndrome","NOT_YET_RECRUITING","2025-09-18",{"date":64,"type":65},"2025-09-23","ACTUAL",{"date":67,"type":54},"2025-10-30",{"date":69,"type":54},"2027-04-30",{"name":5,"class":6}]